Precision Biosciences Says Partner TG Therapeutics Gets U.S. FDA Clearance For Investigational New Drug (Ind) Application To Investigate Azercabtagene Zapreleucel (Azer-cel) In Human Clinical Trials For Multiple Sclerosis
Portfolio Pulse from Benzinga Newsdesk
Precision Biosciences announced that its partner, TG Therapeutics, has received U.S. FDA clearance for an Investigational New Drug (IND) application to investigate Azercabtagene Zapreleucel (Azer-cel) in human clinical trials for multiple sclerosis.
August 09, 2024 | 11:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Precision Biosciences' partner, TG Therapeutics, received FDA clearance for an IND application to investigate Azer-cel in multiple sclerosis trials, potentially boosting DTIL's stock.
The FDA clearance for the IND application is a significant regulatory milestone that could lead to positive sentiment and increased investor interest in Precision Biosciences, as it indicates progress in their partnership with TG Therapeutics.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
TG Therapeutics received FDA clearance for an IND application to investigate Azer-cel in multiple sclerosis trials, which could positively impact TGTX's stock.
The FDA clearance for the IND application is a critical step forward for TG Therapeutics, likely to enhance investor confidence and drive the stock price up due to the potential for successful clinical trials and future market opportunities.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 100